Comparison of Insulin Aspart vs. Regular Human Insulin with or without Insulin Detemir Concerning Adipozytokines and Metabolic Effects in Patients with Type 2 Diabetes Mellitus

Herrmann, Benedikt; Kasser, C; Keuthage, Winfried; Huptas, Michael; Dette, Holger; Klute, A

doi:10.1055/s-0033-1334905

Cited by 9 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our analysis showed that treating poorly controlled patients with BIAsp 30 is likely to be cost-saving and cost-effective in Iran. In parallel to the results of our study, various studies have shown better glycemic control and more tolerability with insulin analogs compared with human insulin in patients with T2DM [ 57 – 59 ]. Subsequently, cost-effectiveness of BIAsp 30 could be attributed to lower incidence of hypoglycemia in short-term and better prevention of DM related complications in long-term [ 60 , 61 ].…”

Section: Discussionsupporting

confidence: 82%

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

et al. 2016

View full text Add to dashboard Cite

BackgroundThe aim of this study was to compare the efficacy, safety, costs, and cost-effectiveness of biphasic insulin aspart 30 (BIAsp 30) with NPH plus regular human insulin (NPH/Reg) in patients with type 2 diabetes mellitus (T2DM).MethodsIt was a Single-center, parallel-group, randomized, clinical trial (Trial Registration: NCT01889095). One hundred and seventy four T2DM patients with poorly controlled diabetes (HbA1c ≥ 8 % (63.9 mmol/mol)) were randomly assigned to trial arms (BIAsp 30 and NPH/Reg) and were followed up for 48 weeks. BIAsp 30 was started at an initial dose of 0.2–0.6 IU/Kg in two divided doses and was titrated according to the glycemic status of the patient. Similarly, NPH/Reg insulin was initiated at a dose of 0.2–0.6 IU/Kg with a 2:1 ratio and was subsequently titrated. Level of glycemic control, hypoglycemic events, direct and indirect costs, quality adjusted life year (QALY) and incremental cost-effectiveness ratio have been assessed.ResultsHbA1c, Fasting plasma glucose (FPG), and two-hour post-prandial glucose (PPG) were improved in both groups during the study (P < 0.05 for all analyses). Lower frequencies of minor, major, and nocturnal hypoglycemic episodes were observed with BIAsp 30 (P < 0.05). Additionally, BIAsp 30 was associated with less weight gain and also higher QALYs (P < 0.05). Total medical and non-medical costs were significantly lower with BIAsp 30 as compared with NPH/Reg (930.55 ± 81.43 USD vs. 1101.24 ± 165.49 USD, P = 0.004). Moreover, BIAsp 30 showed lower ICER as a dominant alternative.ConclusionsDespite being more expensive, BIAsp 30 offers the same glycemic control as to NPH/Reg dose-dependently and also appears to cause fewer hypoglycemic events and to be more cost-effective in Iranian patients with type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 82%

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…1a). Insulin analogues, B28Asp human insulin (insulin aspart) and B29Lys(ε-tetradecanoyl),desB30 human insulin (insulin detemir), also did not change survival rates significantly (electronic supplementary material [ESM] Table 1) [25]. However, human insulin could prevent the lifeshortening effect of HG conditions, increasing mean lifespan under HG conditions from 18.5 ± 0.3 to 20.4 ± 0.9 days ( p<0.05) and maximum lifespan from 25.8±0.3 to 29.7± 0.7 days ( p<0.01) (Fig.…”

Section: Resultsmentioning

confidence: 99%

daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in Caenorhabditis elegans

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Insulin is an effective therapy to decrease the blood glucose levels in type 1 diabetes patients and is a selective therapy in type 2 diabetes patients 8 9 . A type of man-made insulin, protamine zinc insulin (PZI), has been accepted to enhance the medication safety of insulin 10 . However, exogenetic insulin may cause a strong rejection reaction and drug resistance, which restrains the use of insulin 11 .…”

mentioning

confidence: 99%

Protamine zinc insulin combined with sodium selenite improves glycometabolism in the diabetic KKAy mice

Lü

Zhao

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Long-term, high dosage protamine zinc insulin (PZI) treatments produce adverse reactions. The trace element selenium (Se) is a candidate for the prevention of diabetes due to anti-oxidative stress activity and the regulation of glycometabolism. In this study, we aimed to investigate the anti-diabetic effects of a combination of PZI and Se on type 2 diabetes. Diabetic KKAy mice were randomized into the following groups: model group and groups that were subcutaneously injected with PZI, Se, high or low dose PZI + Se for 6 weeks. PZI combined with Se decreased the body weight and fasting blood glucose levels. Moreover, this treatment also improved insulin tolerance, as determined by the reduced values from the oral glucose tolerance test and insulin tolerance test, and increased insulin levels and insulin sensitivity index. PZI combined with Se ameliorated skeletal muscle and β-cell damage and the impaired mitochondrial morphology. Oxidative stress was also reduced. Furthermore, PZI combined with Se upregulated phosphatidylinositol 3-kinase (PI3K) and downregulated protein tyrosine phosphatase 1B (PTP1B). Importantly, the low dosage combination produced effects similar to PZI alone. In conclusion, PZI combined with Se improved glycometabolism and ameliorated the tissue and mitochondrial damage, which might be associated with the PI3K and PTP1B pathways.

show abstract

Comparison of Insulin Aspart vs. Regular Human Insulin with or without Insulin Detemir Concerning Adipozytokines and Metabolic Effects in Patients with Type 2 Diabetes Mellitus

Cited by 9 publications

References 11 publications

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in Caenorhabditis elegans

Protamine zinc insulin combined with sodium selenite improves glycometabolism in the diabetic KKAy mice

Contact Info

Product

Resources

About